Compare Bio-Rad Laboratories, Inc. Class A Common Stock (BIO) vs Okta, Inc. (OKTA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bio-Rad Laboratories, Inc. Class A Common Stock vs Okta, Inc. — how do they compare? Bio-Rad Laboratories, Inc. Class A Common Stock trades at $299.42 (market cap $8.04B), while Okta, Inc. trades at $152 (market cap $26.87B). The key difference: Okta, Inc. is far larger — about 3.3× Bio-Rad Laboratories, Inc. Class A Common Stock's market cap, and Okta, Inc. is trading nearer its 52-week high, Bio-Rad Laboratories, Inc. Class A Common Stock nearer its low. Which is the better fit depends on your goals.
| BIO | OKTA | |
|---|---|---|
Market Cap | $8.04B | $26.87B |
Sector | Health | Technology |
52-Week High | $339.75 | $154.62 |
52-Week Low | $241.71 | $62.93 |
Enterprise Value | $7.85B | $24.70B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BIO trades at $297.58, up 0.5% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $305. The stock shows strong profitability with a 51.87% gross margin and positive net income of $760M in 2025, though recent quarters have seen EPS misses. Cash flow from operations remains robust at $532M, supporting financial stability.
Outlook is cautiously optimistic with analyst support, but risks include earnings volatility and high P/E valuation. The company's return to profitability and solid balance sheet provide a foundation for growth, though investors should monitor execution against future earnings expectations and competitive pressures in the biotech sector.
OKTA trades at $139.53, up 0.65% today, with a bullish technical signal from moving averages. The company reported strong earnings beats in recent quarters, with Q1 2026 EPS of $0.91 exceeding the $0.853 estimate. Revenue grew to $2.61 billion in 2025, and net income turned positive at $28 million. Analyst sentiment is positive, with 72.55% recommending Buy.
The outlook is favorable due to AI-driven demand for cybersecurity, but high valuation multiples pose risks. The stock faces competition and must sustain growth to justify its P/E of 101.11. Upside exists if earnings continue to beat expectations, yet volatility from market sentiment shifts is a concern.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Bio-Rad Laboratories, Inc. Class A Common Stock
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and markets products and solutions for the clinical diagnostics and life sciences markets. In diagnostics (53% of sales), Bio-Rad manufactures, sells, and supports test systems and specialized quality controls for clinical laboratories. In life sciences (47% of sales), the firm develops and manufactures a range of instruments and reagents used in research, biopharmaceutical production, and food testing. The company is geographically diverse, with major markets in the Americas (42% of 2021 sales), Europe and Africa (33%), and Asia-Pacific (25%). Bio-Rad owns 37% of Sartorius AG, a laboratory and biopharmaceutical supplier.
Read more on BIO →About Okta, Inc.
Okta is a cloud-native security company that focuses on identity and access management. The San Francisco-based firm went public in 2017 and focuses on two key client stakeholder groups: workforces and customers. Okta's workforce offerings enable a company's employees to securely access its cloud-based and on-premises resources. The firm's customer offerings allow its clients' customers to securely access the client's applications.
Read more on OKTA →
